JPH08501086A - エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシド - Google Patents
エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシドInfo
- Publication number
- JPH08501086A JPH08501086A JP6506616A JP50661694A JPH08501086A JP H08501086 A JPH08501086 A JP H08501086A JP 6506616 A JP6506616 A JP 6506616A JP 50661694 A JP50661694 A JP 50661694A JP H08501086 A JPH08501086 A JP H08501086A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- dioxolane
- nucleoside
- enantiomerically pure
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒトにおけるHIV感染の治療方法であって、HIV治療量の、以下の構造を有 するエナンチオマー的に純粋なβ-D-ジオキソラニルヌクレオシドを投与する工 程を包含する、方法: ここで、RはOHであり、そしてXは、水素、アルキル、アシル、モノホスフェート 、ジホスフェート、およびトリホスフェート、またはその薬学的に受容可能な塩 からなる群より選択され、そして該化合物は、対応するβ-L-エナンチオマーを9 7%含まない。 2.ヒトにおけるHIV感染の治療方法であって、HIV治療量の、以下の構造を有 するエナンチオマー的に純粋なβ-D-ジオキソラニルヌクレオシドを投与する工 程を包含する、方法: ここで、RはNH2であり、そしてXは、水素、アルキル、アシル、モノホスフェー ト、ジホスフェート、およびトリホスフェート、またはその薬学的に受容可能な 塩からなる群より選択され、そして該化合物は、対応するβ-L-エナンチオマー を97%含まない。 3.ヒトにおけるHIV感染の治療方法であって、HIV治療量の、以下の構造を有 するエナンチオマー的に純粋なβ-D-ジオキソラニルヌクレオシドを投与する工 程を包含する、方法: ここで、RはHまたはClであり、そしてXは、水素、アルキル、アシル、モノホス フェート、ジホスフェート、およびトリホスフェート、またはその薬学的に受容 可能な塩からなる群より選択され、そして該化合物は、対応するβ-L-エナンチ オマーを97%含まない。 4.薬学的組成物であって、以下の構造を有するエナンチオマー的に純粋なβ -D-ジオキサニルヌクレオシドの効果的な量を、薬学的に受容可能なキャリアま たは希釈剤中に含有する、薬学的組成物: ここで、RはOHであり、そしてXは、水素、アルキル、アシル、モノホスフェート 、ジホスフェート、およびトリホスフェート、またはその薬学的に受容可能な塩 からなる群より選択され、そして該化合物は、対応するβ-L-エナンチオマーを9 7%含まない。 5.薬学的組成物であって、以下の構造を有するエナンチオマー的に純粋なβ -D-ジオキサニルヌクレオシドの効果的な量を、薬学的に受容可能なキャリアま たは希釈剤中に含有する、薬学的組成物: ここで、RはNH2であり、そしてXは、水素、アルキル、アシル、モノホスフェー ト、ジホスフェート、およびトリホスフェート、またはその薬学的に受容可能な 塩からなる群より選択され、そして該化合物は、対応するβ-L-エナンチオマー を97%含まない。 6.薬学組成物であって、以下の構造を有するエナンチオマー的に純粋なβ-D -ジオキサニルヌクレオシドの効果的な量を含有する、薬学的組成物: ここて、RはHまたはClであり、そしてXは、水素、アルキル、アシル、モノホス フェート、ジホスフェート、およびトリホスフェート、またはその薬学的に受容 可能な塩からなる群より選択され、そして該化合物は、対応するβ-L-エナンチ オマーを97%含まない。 7.以下の構造を有するエナンチオマー的に純粋なβ-D-ジオキソラニルヌク レオシド: ここで、RはOHであり、そしてXは、水素、アルキル、アシル、モノホスフェート 、ジホスフェート、およびトリホスフェー トからなる群より選択され、そして該化合物は、薬学的に受容可能なキャリアま たは希釈剤中で、対応するβ-L-エナンチオマーを97%含まない。 8.以下の構造を有するエナンチオマー的に純粋なβ-D-ジオキソラニルヌク レオシド: ここで、RはNH2であり、そしてXは、水素、アルキル、アシル、モノホスフェー ト、ジホスフェート、およびトリホスフェートからなる群より選択され、そして 該化合物は、薬学的に受容可能なキャリアまたは希釈剤中で、対応するβ-Lエナ ンチオマーを97%含まない。 9.以下の構造を有するエナンチオマー的に純粋なβ-D-ジオキソラニルヌク レオシド: ここでRはHまたはClであり、そしてXは、水素、アルキル、アシル、モノホスフ ェート、ジホスフェート、およびトリホスフェートからなる群より選択され、そ して該化合物は、対応するβ-L-エナンチオマーを97%含まない。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/935,515 US5925643A (en) | 1990-12-05 | 1992-08-25 | Enantiomerically pure β-D-dioxolane-nucleosides |
US07/935,515 | 1992-08-25 | ||
PCT/US1993/008044 WO1994004154A1 (en) | 1992-08-25 | 1993-08-25 | ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDES |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001251947A Division JP4503206B2 (ja) | 1992-08-25 | 2001-08-22 | エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシド |
JP2003414876A Division JP2004149543A (ja) | 1992-08-25 | 2003-12-12 | エナンチオマー的に純粋なβ−D−ジオキソラン−ヌクレオシド |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08501086A true JPH08501086A (ja) | 1996-02-06 |
JP3519736B2 JP3519736B2 (ja) | 2004-04-19 |
Family
ID=25467279
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50661694A Expired - Fee Related JP3519736B2 (ja) | 1992-08-25 | 1993-08-25 | エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシド |
JP2001251947A Expired - Fee Related JP4503206B2 (ja) | 1992-08-25 | 2001-08-22 | エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシド |
JP2003414876A Pending JP2004149543A (ja) | 1992-08-25 | 2003-12-12 | エナンチオマー的に純粋なβ−D−ジオキソラン−ヌクレオシド |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001251947A Expired - Fee Related JP4503206B2 (ja) | 1992-08-25 | 2001-08-22 | エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシド |
JP2003414876A Pending JP2004149543A (ja) | 1992-08-25 | 2003-12-12 | エナンチオマー的に純粋なβ−D−ジオキソラン−ヌクレオシド |
Country Status (12)
Country | Link |
---|---|
US (2) | US5925643A (ja) |
EP (2) | EP0656778B1 (ja) |
JP (3) | JP3519736B2 (ja) |
AT (2) | ATE498624T1 (ja) |
AU (1) | AU670637C (ja) |
CA (1) | CA2143107C (ja) |
DE (2) | DE69334348D1 (ja) |
DK (1) | DK0656778T3 (ja) |
ES (1) | ES2157929T3 (ja) |
GR (1) | GR3036393T3 (ja) |
PT (1) | PT656778E (ja) |
WO (1) | WO1994004154A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002533470A (ja) * | 1998-12-23 | 2002-10-08 | シャイアー・バイオケム・インコーポレイテッド | 抗ウイルス性ヌクレオシド類似体 |
JP2006504703A (ja) * | 2002-08-06 | 2006-02-09 | フアーマセツト・インコーポレイテツド | 1,3−ジオキソランヌクレオシドの調製方法 |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US6350753B1 (en) | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6346627B1 (en) | 1990-02-01 | 2002-02-12 | Emory University | Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
CA2219132C (en) | 1995-06-07 | 2007-03-06 | Emory University | Nucleosides with anti-hepatitis b virus activity |
US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
US5792773A (en) * | 1996-11-15 | 1998-08-11 | Yale University | L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection |
EA001920B1 (ru) | 1997-03-19 | 2001-10-22 | Эмори Юниверсити | Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b |
DE19739827B4 (de) * | 1997-09-11 | 2007-05-10 | Robert Bosch Gmbh | Verfahren und Vorrichtung zur Steuerung einer Betriebsgröße eines Kraftfahrzeugs |
IL142910A0 (en) | 1998-11-02 | 2002-04-21 | Triangle Pharmaceuticals Inc | Combination therapy to treat hepatitis b virus |
US6511983B1 (en) | 1999-03-01 | 2003-01-28 | Biochem Pharma Inc. | Pharmaceutical combination of antiviral agents |
US6653318B1 (en) | 1999-07-21 | 2003-11-25 | Yale University | 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
WO2001032153A2 (en) * | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
WO2002031176A1 (fr) * | 2000-10-12 | 2002-04-18 | Mitsui Chemicals, Inc. | Procédé permettant la production de nucléosides |
JP5105689B2 (ja) | 2001-03-01 | 2012-12-26 | ギリード・サイエンシズ・インコーポレーテッド | 多形型および他の結晶型のシス−ftc |
RU2344128C2 (ru) | 2003-03-24 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | Бензилпиридазиноны как ингибиторы обратной транскриптазы |
DE602004030369D1 (de) | 2003-10-24 | 2011-01-13 | Immunaid Pty Ltd | Therapieverfahren |
ES2568467T3 (es) * | 2004-02-03 | 2016-04-29 | Emory University | Métodos para la fabricación de nucleósidos de 1,3-dioxolano |
US7446234B2 (en) * | 2005-09-27 | 2008-11-04 | Council Of Scientific And Industrial Research | Bisphenol compound and process for preparation thereof |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
ATE503744T1 (de) | 2006-08-16 | 2011-04-15 | Hoffmann La Roche | Nicht-nukleosidische reverse-transkriptase-hemmer |
KR101475091B1 (ko) | 2006-12-13 | 2014-12-22 | 에프. 호프만-라 로슈 아게 | 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체 |
CA2687747C (en) | 2007-05-30 | 2015-11-17 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
CA2709348C (en) | 2007-12-21 | 2016-07-19 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors for treating human immunodeficiency virus (hiv-1) mediated diseases |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
AU2010251880B2 (en) | 2009-05-27 | 2015-07-30 | Biotempus Pty Ltd | Methods of treating diseases |
WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
EP2552931B1 (en) | 2010-03-31 | 2014-07-23 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4000137A (en) * | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
JPS5668674A (en) * | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
JPH07116042B2 (ja) * | 1985-05-15 | 1995-12-13 | ザ ウエルカム フアウンデ−シヨン リミテツド | ヌクレオシド化合物 |
WO1987001284A1 (en) * | 1985-08-26 | 1987-03-12 | United States Of America, Represented By The Unite | Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine |
US4879277A (en) * | 1985-08-26 | 1989-11-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral compositions and methods |
US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
US4963533A (en) * | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
US5011774A (en) * | 1987-07-17 | 1991-04-30 | Bristol-Myers Squibb Co. | Dideoxyinosine by enzymatic deamination of dideoxyadenosine |
US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US5122517A (en) * | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
DE68922903T2 (de) * | 1988-12-19 | 1995-11-23 | Wellcome Found | Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. |
NZ233197A (en) * | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
US5059690A (en) * | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
US5071983A (en) * | 1989-10-06 | 1991-12-10 | Burroughs Wellcome Co. | Therapeutic nucleosides |
IE904378A1 (en) * | 1989-12-20 | 1991-07-03 | Abbott Lab | Analogs of oxetanyl purines and pyrimidines |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5276151A (en) * | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
WO1992010496A1 (en) * | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
US5248776A (en) * | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
AU653570B2 (en) | 1990-12-14 | 1994-10-06 | Henkel Corporation | Substantially phosphate free mildly acidic cleaner for plastics |
IL100502A (en) * | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
ATE219366T1 (de) * | 1991-03-06 | 2002-07-15 | Univ Emory | Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b |
GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923641B (en) * | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
-
1992
- 1992-08-25 US US07/935,515 patent/US5925643A/en not_active Expired - Lifetime
-
1993
- 1993-08-25 AT AT00203932T patent/ATE498624T1/de not_active IP Right Cessation
- 1993-08-25 PT PT93920366T patent/PT656778E/pt unknown
- 1993-08-25 EP EP93920366A patent/EP0656778B1/en not_active Expired - Lifetime
- 1993-08-25 EP EP00203932A patent/EP1081148B1/en not_active Expired - Lifetime
- 1993-08-25 DE DE69334348T patent/DE69334348D1/de not_active Expired - Lifetime
- 1993-08-25 JP JP50661694A patent/JP3519736B2/ja not_active Expired - Fee Related
- 1993-08-25 AU AU50933/93A patent/AU670637C/en not_active Withdrawn - After Issue
- 1993-08-25 CA CA002143107A patent/CA2143107C/en not_active Expired - Lifetime
- 1993-08-25 DK DK93920366T patent/DK0656778T3/da active
- 1993-08-25 WO PCT/US1993/008044 patent/WO1994004154A1/en active IP Right Grant
- 1993-08-25 DE DE69330274T patent/DE69330274T2/de not_active Expired - Lifetime
- 1993-08-25 ES ES93920366T patent/ES2157929T3/es not_active Expired - Lifetime
- 1993-08-25 AT AT93920366T patent/ATE201599T1/de active
-
1995
- 1995-06-06 US US08/469,465 patent/US5767122A/en not_active Expired - Lifetime
-
2001
- 2001-08-14 GR GR20010401249T patent/GR3036393T3/el unknown
- 2001-08-22 JP JP2001251947A patent/JP4503206B2/ja not_active Expired - Fee Related
-
2003
- 2003-12-12 JP JP2003414876A patent/JP2004149543A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002533470A (ja) * | 1998-12-23 | 2002-10-08 | シャイアー・バイオケム・インコーポレイテッド | 抗ウイルス性ヌクレオシド類似体 |
JP2006504703A (ja) * | 2002-08-06 | 2006-02-09 | フアーマセツト・インコーポレイテツド | 1,3−ジオキソランヌクレオシドの調製方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE201599T1 (de) | 2001-06-15 |
EP0656778A1 (en) | 1995-06-14 |
DE69334348D1 (de) | 2011-03-31 |
DE69330274D1 (de) | 2001-07-05 |
CA2143107C (en) | 2004-11-23 |
AU670637B2 (en) | 1996-07-25 |
AU670637C (en) | 2002-07-25 |
JP4503206B2 (ja) | 2010-07-14 |
GR3036393T3 (en) | 2001-11-30 |
ATE498624T1 (de) | 2011-03-15 |
EP1081148A3 (en) | 2003-03-05 |
WO1994004154A1 (en) | 1994-03-03 |
EP1081148B1 (en) | 2011-02-16 |
JP2002114787A (ja) | 2002-04-16 |
ES2157929T3 (es) | 2001-09-01 |
JP2004149543A (ja) | 2004-05-27 |
AU5093393A (en) | 1994-03-15 |
EP1081148A2 (en) | 2001-03-07 |
JP3519736B2 (ja) | 2004-04-19 |
US5767122A (en) | 1998-06-16 |
CA2143107A1 (en) | 1994-03-03 |
DE69330274T2 (de) | 2001-11-15 |
DK0656778T3 (da) | 2001-07-30 |
EP0656778A4 (en) | 1995-08-02 |
EP0656778B1 (en) | 2001-05-30 |
US5925643A (en) | 1999-07-20 |
PT656778E (pt) | 2001-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4503206B2 (ja) | エナンチオマー的に純粋なβ‐D‐ジオキソラン−ヌクレオシド | |
JP3421335B2 (ja) | 鏡像異性的に純粋なβ−D−(−)−ジオキソラン−ヌクレオシド | |
JP3117217B2 (ja) | 選択的な抗B型肝炎ウイルス活性を有する鏡像体的に純粋なβ−D−ジオキソランヌクレオシド | |
WO1994004154A9 (en) | ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDES | |
RU2126405C1 (ru) | (-)-4-амино-5-фтор-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1h)-пиримидин- 2-он, смесь его энантиомеров, способы их получения, способ лечения | |
EP0805683B1 (en) | 5-fluoro-2',3'-unsaturated-pyrimidine nucleosides | |
AU2003200421B2 (en) | Enantiomerically pure beta-D-dioxolane-nucleosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040130 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090206 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100206 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100206 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110206 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120206 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120206 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130206 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |